Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

175 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Risk of hemoptysis in patients with resected squamous cell and other high-risk lung cancers treated with adjuvant bevacizumab.
Hellmann MD, Chaft JE, Rusch V, Ginsberg MS, Finley DJ, Kris MG, Price KA, Azzoli CG, Fury MG, Riely GJ, Krug LM, Downey RJ, Bains MS, Sima CS, Rizk N, Travis WD, Rizvi NA, Paik PK. Hellmann MD, et al. Cancer Chemother Pharmacol. 2013 Aug;72(2):453-61. doi: 10.1007/s00280-013-2219-5. Epub 2013 Jun 28. Cancer Chemother Pharmacol. 2013. PMID: 23811982 Free PMC article. Clinical Trial.
Chemotherapy for lung cancers: here to stay.
Kris MG, Hellmann MD, Chaft JE. Kris MG, et al. Among authors: hellmann md. Am Soc Clin Oncol Educ Book. 2014:e375-80. doi: 10.14694/EdBook_AM.2014.34.e375. Am Soc Clin Oncol Educ Book. 2014. PMID: 24857127 Review.
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.
Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS, Miller ML, Rekhtman N, Moreira AL, Ibrahim F, Bruggeman C, Gasmi B, Zappasodi R, Maeda Y, Sander C, Garon EB, Merghoub T, Wolchok JD, Schumacher TN, Chan TA. Rizvi NA, et al. Among authors: hellmann md. Science. 2015 Apr 3;348(6230):124-8. doi: 10.1126/science.aaa1348. Epub 2015 Mar 12. Science. 2015. PMID: 25765070 Free PMC article.
Pembrolizumab for the treatment of non-small-cell lung cancer.
Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E, Ahn MJ, Felip E, Lee JS, Hellmann MD, Hamid O, Goldman JW, Soria JC, Dolled-Filhart M, Rutledge RZ, Zhang J, Lunceford JK, Rangwala R, Lubiniecki GM, Roach C, Emancipator K, Gandhi L; KEYNOTE-001 Investigators. Garon EB, et al. Among authors: hellmann md. N Engl J Med. 2015 May 21;372(21):2018-28. doi: 10.1056/NEJMoa1501824. Epub 2015 Apr 19. N Engl J Med. 2015. PMID: 25891174 Clinical Trial.
Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.
Gettinger SN, Horn L, Gandhi L, Spigel DR, Antonia SJ, Rizvi NA, Powderly JD, Heist RS, Carvajal RD, Jackman DM, Sequist LV, Smith DC, Leming P, Carbone DP, Pinder-Schenck MC, Topalian SL, Hodi FS, Sosman JA, Sznol M, McDermott DF, Pardoll DM, Sankar V, Ahlers CM, Salvati M, Wigginton JM, Hellmann MD, Kollia GD, Gupta AK, Brahmer JR. Gettinger SN, et al. Among authors: hellmann md. J Clin Oncol. 2015 Jun 20;33(18):2004-12. doi: 10.1200/JCO.2014.58.3708. Epub 2015 Apr 20. J Clin Oncol. 2015. PMID: 25897158 Free PMC article. Clinical Trial.
Combinatorial Cancer Immunotherapies.
Hellmann MD, Friedman CF, Wolchok JD. Hellmann MD, et al. Adv Immunol. 2016;130:251-77. doi: 10.1016/bs.ai.2015.12.005. Epub 2016 Jan 12. Adv Immunol. 2016. PMID: 26923003 Review.
175 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page